Evidentic Blog

Types of Anti-idiotype antibodies


Development of anti-drug antibody (ADA) – based assays

Administration of Biotherapeutics into patients may provoke an immune response leading to the development of anti-drug antibodies (ADAs). ADAs affect the product's pharmacokinetic profile, pharmacodynamic effect, clinical efficacy or safety.

Structure of Chimeric Antigen Receptors (CARs)

Scientific Resources

Cell therapy using Chimeric antigen receptors – CARs

CAR-T, CAR-NK and CAR-M cell therapie

Therapeutic mAbs

Antibody drug conjugates (ADC) for therapy

Delivering chemotherapy with the specificity of monoclonal antibodies!

Scientific Resources

Endotoxin levels in Biologics!

Know your Biologic’s endotoxin levels!

Therapeutic mAbs, Analytics, News

Host Cell Protein analysis for biologics development

What are host cell proteins in biologic drugs?

News, Therapeutic mAbs

Critical Quality Attributes (CQAs) of Biologic Drugs

Defining critical quality attributes of biologics

Therapeutic mAbs, News, Scientific Resources

Therapeutic antibodies as Immune checkpoint inhibitors

Immunotherapy and Immune checkpoint inhibitors

Bispecific Antibodies

Bispecific antibodies, Therapeutic mAbs

Bispecific Antibodies: Coming-of-age in Antibody Therapeutics (Part 2 of 2)

Bispecific Antibodies: Therapeutic applications and clinical pipeline. Bispecific antibodies have triggered considerable interest in the medical field and in the pharmaceutical industry over the last few years.


Excipients: The inactive ingredients of biologics!

What are excipients for biologics?

Therapeutic mAbs, Biosimilars

Therapeutic Antibodies to Treat Cancer Targeting CD20

Therapeutic antibodies for cancer targeting CD20 have been successfully used in immunotherapies to treat B-cell malignancies and auto-immune diseases.

Therapeutic mAbs, Biosimilars

Characterization of Therapeutic Monoclonal Antibodies

Characterization of therapeutic monoclonal antibodies are important to screen the right mAb molecule by defining the critical quality attributes.

Therapeutic mAbs, Biosimilars

Reference Standards for Biosimilar Development

It is important to first establish a reference standard while assessing biosimilarity between a biosimilar product and the reference product.

Bispecific antibodies, News

Bispecific Antibodies: Coming-of-age in antibody therapeutics (Part 1 of 2)

Discovery of antibodies, also known as immunoglobulins, paved way for the evolution of protein-based therapeutic molecules (biologics).


Reference Drugs for Biopharmaceuticals

Evidentic GmbH today announced the availability of reference drugs in aliquot format for the biopharma industry.

Therapeutic mAbs

Monoclonal Antibody Therapy

Monoclonal antibody therapies have elevated precision medicine by enabling targeted therapy and providing personalized treatment options.

Therapeutic mAbs

The Advent of Therapeutic Antibodies

Antibodies are important components of the immune system that confer specific immunity. The specific targeting ability of antibodies has been exploited in research and medical diagnosis since decades.


Biosimilar Development: Role of Reference Therapeutic Antibody Drugs

Monoclonal antibodies (mAbs) are an important class of biologics that have altered the treatment landscapes in several therapeutic areas such as cancer, auto-immune diseases, and viral infections.

Scientific Resources

Biosimilar characterization – scientific resources

Some interesting scientific resources on biosimilar characterization

Scientific Resources

SARS-CoV-2 – scientific resources

Some interesting scientific resources on SARS-CoV-2

Scientific Resources

Therapeutic antibodies – scientific resources

Some interesting developments in the field of therapeutic antibodies


Reduced Costs for Acquiring Reference Drugs for Biopharma Industry

Evidentic GmbH today announced the availability of reference drugs in aliquot format for the biopharma industry.


Biosimilar comparability exercise

The biosimilar comparability exercise is a series of studies characterizing quality attributes of a reference and a biosimilar product. Approval of the biosimilar product by regulatory agencies is based on demonstrating high similarity between reference and biosimilar products. Guidelines for the conducting of biosimilar comparability exercises have been published by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).


For Biosimilar Developers

Reference products for biosimilar manufacturers – Your hassle-free reference medicinal product source for biosimilar analytics


Biosimilar Technology

Biosimilars: biologicals made accessible

Therapeutic mAbs

Anti-IL-6R mABs for Rheumatoid Arthritis

Cytokines are singalling protein, peptide or glycoproteins molecules that are secreted by cells of immune system. They act of different cell types to regulate the immune response, inflammatory responses, cell growth, cell migration, fibrosis, and angiogenesis.

Therapeutic mAbs

Biologic Drugs for Rheumatoid Arthritis

The disease rheumatoid arthritis (RA) is a manifestation of a chronic inflammatory disorder. It is a common autoimmune disorder that affects approx. 0.5%–1% of the adult population. It is characterized by inflammation of synovium accompanied by articular bone and cartilage damage.


Certificate of Analysis (CoA)

A Certificate of Analysis (CoA) is an important document provided with a range of manufactured products like food, chemicals, research products, and pharmaceutical products.

Evidentic Support
+49 (0) 30 959 99 8831

Let us know about your inquiry details and we’ll contact you shortly.